Ubs Asset Management Americas Inc Ab Cellera Biologics Inc. Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 4,598,626 shares of ABCL stock, worth $12.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,598,626Holding current value
$12.6 Million% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ABCL
# of Institutions
165Shares Held
119MCall Options Held
239KPut Options Held
200K-
Baker Bros. Advisors LP New York, NY27.5MShares$75.7 Million1.08% of portfolio
-
Baillie Gifford & CO21.9MShares$60.3 Million0.05% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$29.2 Million0.04% of portfolio
-
Capital World Investors Los Angeles, CA5.32MShares$14.6 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V84.55MShares$12.5 Million0.02% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $784M
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...